Trends in the biological functions and medical applications of extracellular vesicles and analogues

Zhao, Yan; Li, Xiaolu; Zhang, Wenbo; Yu, Lanlan; Wang, Yang; Deng, Zhun; Liu, Mingwei; Mo, Shanshan; Wang, Ruonan; Zhao, Jin; Liu, Shuli; Hao, Yun; Wang, Xiangdong; Ji, Tianjiao; Zhang, Luo; Wang, Chenxuan

doi:10.1016/j.apsb.2021.03.012

Cited by 36 publications

(42 citation statements)

References 249 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, viral vectors have disadvantages as well, e.g., the phage vector has a low loading capacity and needs sufficient studies, while in the case of lentiviral vectors, random genomic integration might result in the insertional mutation [ 231 ]. In terms of non-viral delivery systems, the exosome-based method is one of the most promising [ 231 ], although the difficulty of preparation hinders its development [ 232 ]. In hair growth studies, mostly lipofectamine (in vitro) [ 7 , 76 , 177 , 189 , 190 ] and in vivo jetPEI [ 77 ] are used as delivery systems.…”

Section: Main Challenge: Delivery Systemsmentioning

confidence: 99%

Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy

Papukashvili

Rcheulishvili

Liu

et al. 2021

Cells

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) remains an unsolved problem for the well-being of humankind, although multiple important involvements in hair growth have been discovered. Up until now, there is no ideal therapy in clinical practice in terms of efficacy and safety. Ultimately, there is a strong need for developing a feasible remedy for preventing and treating AGA. The Wnt/β-catenin signaling pathway is critical in hair restoration. Thus, AGA treatment via modulating this pathway is rational, although challenging. Dickkopf-related protein 1 (DKK1) is distinctly identified as an inhibitor of canonical Wnt/β-catenin signaling. Thus, in order to stimulate the Wnt/β-catenin signaling pathway, inhibition of DKK1 is greatly demanding. Studying DKK1-targeting microRNAs (miRNAs) involved in the Wnt/β-catenin signaling pathway may lay the groundwork for the promotion of hair growth. Bearing in mind that DKK1 inhibition in the balding scalp of AGA certainly makes sense, this review sheds light on the perspectives of miRNA-mediated hair growth for treating AGA via regulating DKK1 and, eventually, modulating Wnt/β-catenin signaling. Consequently, certain miRNAs regulating the Wnt/β-catenin signaling pathway via DKK1 inhibition might represent attractive candidates for further studies focusing on promoting hair growth and AGA therapy.

show abstract

Section: Main Challenge: Delivery Systemsmentioning

confidence: 99%

Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy

Papukashvili

Rcheulishvili

Liu

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Starting from 2006, several groups reported that EVs could contain and transfer biomolecules present in the cytosol of originating cells [ 1 ], including mRNA and miRNA [ 2 ], proteins, lipids and metabolites [ 3 ]. The bioactive materials are protected by the vesicles from the extracellular environment and shuttled to neighboring or considerably distant cells, triggering functional changes in the recipient cells and regulating many physiological and pathological processes [ 4 ]. The discovery of their role of intercellular messengers, made EVs compelling candidates for the development of innovative therapeutic tools.…”

Section: Introductionmentioning

confidence: 99%

“…Thanks to these promising features, EVs have been recently evaluated as efficient carriers for the delivery of therapeutic cargos like small molecule drugs, nucleic acids, genes and even NPs for the treatment of various pathologies, including neurodegenerative and cardiovascular diseases, inflammation, diabetes [ 4 ] and especially cancer. According to a query done on July 2021 on the US-NIH clinical trials database, 324 clinical trials on EVs or exosomes are currently registered, 121 of which refer to their use for both diagnostic and therapeutic oncological purposes.…”

Section: Introductionmentioning

confidence: 99%

Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices

et al. 2022

View full text Add to dashboard Cite

Background We propose an efficient method to modify B-cell derived EVs by loading them with a nanotherapeutic stimuli-responsive cargo and equipping them with antibodies for efficient targeting of lymphoma cells. Results The post-isolation engineering of the EVs is accomplished by a freeze–thaw method to load therapeutically-active zinc oxide nanocrystals (ZnO NCs), obtaining the so-called TrojanNanoHorse (TNH) to recall the biomimetism and cytotoxic potential of this novel nanoconstruct. TNHs are further modified at their surface with anti-CD20 monoclonal antibodies (TNHCD20) achieving specific targeting against lymphoid cancer cell line. The in vitro characterization is carried out on CD20+ lymphoid Daudi cell line, CD20-negative cancerous myeloid cells (HL60) and the healthy counterpart (B lymphocytes). The TNH shows nanosized structure, high colloidal stability, even over time, and good hemocompatibility. The in vitro characterization shows the high biocompatibility, targeting specificity and cytotoxic capability. Importantly, the selectivity of TNHCD20 demonstrates significantly higher interaction towards the target lymphoid Daudi cell line compared to the CD20-negative cancerous myeloid cells (HL60) and the healthy counterpart (lymphocytes). An enhanced cytotoxicity directed against Daudi cancer cells is demonstrated after the TNHCD20 activation with high-energy ultrasound shock-waves (SW). Conclusion This work demonstrates the efficient re-engineering of EVs, derived from healthy cells, with inorganic nanoparticles and monoclonal antibodies. The obtained hybrid nanoconstructs can be on-demand activated by an external stimulation, here acoustic pressure waves, to exploit a cytotoxic effect conveyed by the ZnO NCs cargo against selected cancer cells. Graphical Abstract

show abstract

“…EXOs are endogenous extracellular nanovesicles deriving from the endosomal system with a particle size ranging from 30 to 150 nm. EXOs are released by various types of cells into the extracellular environment as nature’s nano delivery system of lipids, proteins, and nucleic acids, playing an important role in intercellular communication 134 , 135 , 136 , 144 .…”

Section: Sirna Delivery Systems For Treatment Of Ali/ardsmentioning

confidence: 99%

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Zoulikha

Xiao

Boafo

et al. 2022

Acta Pharmaceutica Sinica B

142

View full text Add to dashboard Cite

The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the clinical translation of siRNA is hampered by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic.

show abstract

Trends in the biological functions and medical applications of extracellular vesicles and analogues

Cited by 36 publications

References 249 publications

Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy

Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy

Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Contact Info

Product

Resources

About